Cilta-Cel Receives Positive Recommendation for Updated Indication in Myeloma
Blood Cancers Today Staff WritersMyeloma | March 15, 2024

The FDA Oncologic Drugs Advisory Committee (ODAC) voted on whether the risk-benefit assessment for cilta-cel is sufficient evidence to recommend the approval of a supplemental Biologics License Application for an updated indication.

Advertisement
Advertisement

Advertisement
Advertisement
Editorial Board

Podcasts

Chadi Nabhan, MD, MBA, FACPAcute Lymphoblastic Leukemia | March 14, 2024
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Listen Now
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 29, 2024
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 15, 2024
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 15, 2024
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
Chadi Nabhan, MD, MBA, FACPMyelodysplastic Syndromes | February 14, 2024
This episode of The HemOnc Pulse features Dr. Shastri, a physician-scientist, who discusses latest news in MDS.
Chadi Nabhan, MD, MBA, FACPHodgkin Lymphoma | January 4, 2024
Susan Parsons, MD, MRP; Andrew Evans, DO, MBA, MSc; and Matthew Maurer, DMSc; discuss the HoLISTIC consortium.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Venugopal offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes.

Video Insights

Knowledge Hubs

Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia

Trending on MashupMD

Network Websites